Novo Nordisk indicated that only one type of its insulin is in shortage. Manufacturing delays will cause Novo's Fiasp vials to be in short supply through October, a Novo spokesperson said.

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

This prospective, randomized, controlled, parallel-group study compared the use of pen devices with conventional vials ... insulin pen devices were used: InnoLet and FlexPen (Novo Nordisk).